These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
198 related articles for article (PubMed ID: 10754776)
21. Comparison between the positive inotropic effects of enoximone, a cardiac phosphodiesterase III inhibitor, and dobutamine in patients with moderate to severe congestive heart failure. A study using the end-systolic pressure-volume relationship method. Installe E; De Coster P; Gonzalez M; Brichant C; Lessire H; Cauwe F Eur Heart J; 1991 Sep; 12(9):985-93. PubMed ID: 1834466 [TBL] [Abstract][Full Text] [Related]
22. Phosphodiesterase III inhibition or adrenoreceptor stimulation: milrinone as an alternative to dobutamine in the treatment of severe heart failure. Mager G; Klocke RK; Kux A; Höpp HW; Hilger HH Am Heart J; 1991 Jun; 121(6 Pt 2):1974-83. PubMed ID: 1852090 [TBL] [Abstract][Full Text] [Related]
23. Comparative hemodynamic effects of OPC-18790 and dobutamine in patients with advanced heart failure. Abraham WT; Lowes BD; White M; Ferguson DA; Scheffel CA; Wolfel EE; Lindenfeld J; Bristow MR J Card Fail; 1994 Oct; 1(1):57-62. PubMed ID: 9420633 [TBL] [Abstract][Full Text] [Related]
24. Weaning from inotropic support and concomitant beta-blocker therapy in severely ill heart failure patients: take the time in order to improve prognosis. Constantinescu AA; Caliskan K; Manintveld OC; van Domburg R; Jewbali L; Balk AH Eur J Heart Fail; 2014 Apr; 16(4):435-43. PubMed ID: 24464574 [TBL] [Abstract][Full Text] [Related]
25. Identification of viable myocardium early after acute myocardial infarction under beta-blockade by enoximone echocardiography. Natale E; Minardi G; Wang F; Tubaro M; Giovannini E; Vajola SF; Milazzotto F G Ital Cardiol; 1997 Apr; 27(4):342-8. PubMed ID: 9199952 [TBL] [Abstract][Full Text] [Related]
26. IV milrinone for cardiac output increase and maintenance: comparison in nonhyperdynamic SIRS/sepsis and congestive heart failure. Heinz G; Geppert A; Delle Karth G; Reinelt P; Gschwandtner ME; Neunteufl T; Zauner C; Frossard M; Siostrzonek P Intensive Care Med; 1999 Jun; 25(6):620-4. PubMed ID: 10416916 [TBL] [Abstract][Full Text] [Related]
27. [Enoximone, vasodilator and/or inotropic agent in congestive cardiac insufficiency? Hemodynamic and ventriculographic study of 20 cases]. Durrieu C; Rochoux G; Coste P; Le Goff G; Besse P Arch Mal Coeur Vaiss; 1990 Sep; 83 Spec No 3():43-50. PubMed ID: 2147834 [TBL] [Abstract][Full Text] [Related]
28. [Refractory heart failure. Positive inotropes and beta blockers: alternative or complementary treatments?]. Sabbadini G; Ciaccheri M; Castelli G; Sinagra G; Di Lenarda A Ital Heart J Suppl; 2002 Aug; 3(8):804-11. PubMed ID: 12407835 [TBL] [Abstract][Full Text] [Related]
29. Enoximone (MDL 17,043), a phosphodiesterase inhibitor, in the treatment of advanced, unstable chronic heart failure. Weber KT; Janicki JS; Jain MC J Heart Transplant; 1986; 5(2):105-12. PubMed ID: 2956397 [TBL] [Abstract][Full Text] [Related]
30. Hemodynamic effects of dobutamine in patients with an exacerbation of chronic systolic heart failure treated with low doses of carvedilol. Triposkiadis F; Dalampiras P; Kelepeshis G; Skoularigis J; Sitafidis G Int J Clin Pharmacol Ther; 2008 Mar; 46(3):136-9. PubMed ID: 18397684 [TBL] [Abstract][Full Text] [Related]
31. Low-dose β-blocker in combination with milrinone safely improves cardiac function and eliminates pulsus alternans in patients with acute decompensated heart failure. Kobayashi S; Susa T; Tanaka T; Murakami W; Fukuta S; Okuda S; Doi M; Wada Y; Nao T; Yamada J; Okamura T; Yano M; Matsuzaki M Circ J; 2012; 76(7):1646-53. PubMed ID: 22481100 [TBL] [Abstract][Full Text] [Related]
32. Arterial baroreflex sensitivity is a good predictor of inotropic responses to a phosphodiesterase inhibitor in human heart failure. Sato N; Yamamoto T; Akutsu K; Fujita N; Asai K; Takayama M; Takano T; Tanaka K Clin Cardiol; 2006 Jun; 29(6):263-7. PubMed ID: 16796077 [TBL] [Abstract][Full Text] [Related]
33. Addition of a β1-Blocker to Milrinone Treatment Improves Cardiac Function in Patients with Acute Heart Failure and Rapid Atrial Fibrillation. Kobayashi S; Myoren T; Kajii T; Kohno M; Nanno T; Ishiguchi H; Nishimura S; Fukuda M; Hino A; Fujimura T; Ono M; Uchinoumi H; Tateishi H; Mochizuki M; Oda T; Okuda S; Yoshiga Y; Kawano R; Yano M Cardiology; 2019; 142(4):195-202. PubMed ID: 31137022 [TBL] [Abstract][Full Text] [Related]
34. Pharmacologic and hemodynamic effects of combined beta-agonist stimulation and phosphodiesterase inhibition in the failing human heart. Gilbert EM; Hershberger RE; Wiechmann RJ; Movsesian MA; Bristow MR Chest; 1995 Dec; 108(6):1524-32. PubMed ID: 7497755 [TBL] [Abstract][Full Text] [Related]
35. Tolerability of beta-blockers in outpatients with refractory heart failure who were receiving continuous milrinone. Earl GL; Verbos-Kazanas MA; Fitzpatrick JM; Narula J Pharmacotherapy; 2007 May; 27(5):697-706. PubMed ID: 17461705 [TBL] [Abstract][Full Text] [Related]
36. Palliative Inotropes in Advanced Heart Failure: Comparing Outcomes Between Milrinone and Dobutamine. Sami F; Acharya P; Noonan G; Maurides S; Al-Masry AA; Bajwa S; Parimi N; Boda I; Tran C; Goyal A; Mastoris I; Dalia T; Sauer A; Bakel AV; Shah Z J Card Fail; 2022 Dec; 28(12):1683-1691. PubMed ID: 36122816 [TBL] [Abstract][Full Text] [Related]
37. The use of levosimendan in comparison and in combination with dobutamine in the treatment of decompensated heart failure. Cavusoglu Y Expert Opin Pharmacother; 2007 Apr; 8(5):665-77. PubMed ID: 17376021 [TBL] [Abstract][Full Text] [Related]